Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT1306 and BAT8001 in HER2-positive Advanced Solid Tumors
NCT04151329Phase 2Unknown
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Jun 2019
- Primary completion
- Dec 2020
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label trial of BAT8001 in HER2-positive solid tumor (2 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoints: Dose-limiting toxicity at 3 weeks, Area under the curve at 3 weeks and 4 more. Status: unknown.
02
Drugs
BAT8001
03
Conditions
HER2-positive solid tumor
Beyond the preview
Go deeper on NCT04151329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04151329.